ESPR Q2 2022 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$19M-53.7% YoY

Gross Profit

$10M51.3% margin

Operating Income

-$52M-278.0% margin

Net Income

-$66M-352.0% margin

EPS (Diluted)

$-1.27

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$51M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$304M

Total Liabilities

$596M

Stockholders' Equity

-$292M

Cash & Equivalents

$123M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$41M	-53.7%
Gross Profit	$10M	$39M	-75.1%
Operating Income	-$52M	-$33M	-61.0%
Net Income	-$66M	-$44M	-51.9%

Revenue Segments

Collaboration Revenue

$5M51%

Royalty Revenue And Product Sales Bulk Tablets

$5M49%